Researchers have used AI to find adalimumab effective for iMCD, highlighting the potential of machine learning in discovering ...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.

Postdoctoral scholar Daniela Soto has earned a prestigious fellowship from HHMI with eight years of funding to study the ...

Genomenon, Inc., a leading provider of genomic intelligence solutions, has announced a strategic partnership with Mirum Pharmaceuticals, Inc. to improve the awareness and diagnosis of Cerebrotendinous ...

LIG4 syndrome is an exceptionally rare disorder caused by a genetic mutation that prevents the body from repairing damaged ...

Genetic variants linked to autism are associated with structural differences in neonatal white matter, particularly increased ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

In honor of Rare Disease Day on February 28, 2025, Morgan Lewis is publishing a series of posts on As Prescribed and Health ...

Candidate genetic variants included in a genetic risk algorithm may not meet standards of reasonable clinical efficacy in identifying opioid use disorder risk, according to a study published in JAMA ...

Regular screenings for all patients should begin at age 20 and proceed in intervals. However, if you're at high risk for ...

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.